Profile data is unavailable for this security.
About the company
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. The Company’s clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that is designed with its proprietary single domain antibody, or sdAb, platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist, being investigated as a single agent and in combination with Keytruda, a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors. INBRX-106 is a precisely engineered hexavalent sdAb-based therapeutic candidate targeting OX40, designed to be an optimized agonist of this co-stimulatory receptor.
- Revenue in USD (TTM)1.85m
- Net income in USD1.63bn
- Incorporated2024
- Employees166.00
- LocationInhibrx Biosciences Inc11025 N. Torrey Pines Road, Suite 140LA JOLLA 92037United StatesUSA
- Phone+1 (858) 795-4220
- Fax+1 (302) 636-5454
- Websitehttps://inhibrx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Telomir Pharmaceuticals Inc | 0.00 | -18.74m | 124.07m | 1.00 | -- | 79.14 | -- | -- | -0.6855 | -0.6855 | 0.00 | 0.0529 | 0.00 | -- | -- | 0.00 | -467.16 | -- | -686.91 | -- | -- | -- | -- | -- | -- | -0.9299 | 0.00 | -- | -- | -- | -1,430.39 | -- | -- | -- |
Hongchang International Co Ltd | 4.65m | -292.22k | 125.56m | 8.00 | -- | 3.20 | -- | 27.01 | -0.0006 | -0.0006 | 0.0093 | 0.0757 | 0.1647 | 5.02 | 8.74 | -- | -0.8827 | -7.98 | -0.9331 | -10.94 | 3.92 | 11.47 | -5.36 | -64.88 | 3.77 | -- | 0.2642 | -- | 3,289.22 | -- | -42.63 | -- | -- | -- |
Elutia Inc | 24.99m | -70.10m | 129.43m | 54.00 | -- | -- | -- | 5.18 | -3.05 | -2.86 | 1.12 | -2.28 | 0.5303 | 2.32 | 5.08 | 462,722.20 | -148.77 | -42.93 | -1,212.93 | -79.34 | 42.46 | 43.32 | -280.53 | -64.16 | 0.6842 | -0.6561 | -- | -- | -49.69 | -8.71 | -25.39 | -- | 12.74 | -- |
Global Pharmatech Inc. | 3.18m | -2.24m | 138.32m | 217.00 | -- | 1.02 | -- | 43.51 | -0.0964 | -0.0964 | 0.1367 | 0.3428 | 0.2292 | 1.59 | 3.57 | 14,649.77 | -16.44 | -- | -22.55 | -- | 46.21 | -- | -71.75 | -- | 1.62 | -9.87 | 0.2223 | -- | 32.43 | -- | -142.03 | -- | -- | -- |
Scilex Holding Co | 50.83m | -171.53m | 147.53m | 113.00 | -- | -- | -- | 2.90 | -1.40 | -1.40 | 0.4425 | -1.77 | 0.4401 | 5.22 | 1.55 | 484,123.80 | -102.93 | -- | -- | -- | 68.24 | -- | -233.88 | -- | 0.1853 | -3.72 | -- | -- | 22.90 | -- | -614.67 | -- | -- | -- |
LifeVantage Corp | 196.01m | 4.13m | 172.10m | 217.00 | 43.05 | 6.19 | 22.66 | 0.878 | 0.3192 | 0.3192 | 15.27 | 2.22 | 3.06 | 2.50 | 71.64 | 903,290.30 | 6.46 | 9.95 | 10.17 | 15.55 | 79.21 | 81.45 | 2.11 | 3.08 | 0.9923 | 559.36 | 0.00 | 26.95 | -6.20 | -2.40 | 15.63 | -16.94 | -2.18 | -- |
Mediwound Ltd | 20.14m | -19.97m | 182.40m | 100.00 | -- | 8.79 | -- | 9.06 | -2.16 | -2.16 | 2.18 | 1.92 | 0.3311 | 5.53 | 6.55 | 201,410.00 | -32.83 | -24.48 | -49.28 | -32.92 | 13.25 | 43.27 | -99.17 | -38.43 | 1.51 | -3.26 | 0.2623 | -- | -29.48 | 40.60 | 65.73 | -- | 64.66 | -- |
Scpharmaceuticals Inc | 24.05m | -60.64m | 196.61m | 135.00 | -- | 15.35 | -- | 8.18 | -1.56 | -1.56 | 0.6187 | 0.256 | 0.2678 | 0.6563 | 6.23 | 178,133.30 | -67.52 | -38.23 | -75.77 | -42.31 | 71.15 | -- | -252.18 | -1,360.16 | 3.66 | -13.66 | 0.8121 | -- | -- | -- | -48.79 | -- | -- | -- |
Eton Pharmaceuticals Inc | 31.38m | -6.69m | 236.92m | 30.00 | -- | 17.54 | -- | 7.55 | -0.2596 | -0.2596 | 1.22 | 0.5229 | 1.00 | 8.82 | 7.89 | 1,046,033.00 | -21.31 | -46.22 | -38.27 | -58.20 | 59.48 | 72.16 | -21.31 | -76.86 | 1.28 | -- | 0.2571 | -- | 48.90 | -- | 89.62 | -- | 26.85 | -- |
Inhibrx Biosciences Inc | 1.85m | 1.63bn | 240.01m | 166.00 | 0.1368 | 1.09 | 0.1466 | 129.53 | 121.21 | 121.21 | 0.0434 | 15.15 | 0.0079 | -- | 4.86 | 11,162.65 | 693.63 | -77.06 | 815.31 | -93.91 | -- | -- | 88,264.55 | -1,590.91 | -- | -21.96 | 0.00 | -- | -17.88 | -26.85 | -66.20 | -- | 26.30 | -- |
Lifecore Biomedical Inc | 128.45m | 5.71m | 258.53m | 524.00 | 190.04 | -- | 17.96 | 2.01 | 0.0369 | 0.0595 | 3.82 | 1.28 | 0.5217 | 2.01 | 4.96 | 245,124.00 | 2.32 | -5.91 | 2.74 | -8.33 | 34.65 | 31.01 | 4.45 | -19.16 | 0.803 | 0.125 | 0.7641 | -- | 24.20 | -25.46 | 114.53 | 34.47 | -16.72 | -- |
Precigen Inc | 4.39m | -135.38m | 271.15m | 202.00 | -- | 5.56 | -- | 61.78 | -0.5407 | -0.5407 | 0.0176 | 0.1709 | 0.0313 | -- | 4.71 | 21,727.72 | -96.46 | -31.50 | -119.34 | -38.63 | -13.56 | 44.00 | -3,084.55 | -232.32 | -- | -- | 0.00 | -- | -76.87 | -47.16 | -20.22 | -- | -48.30 | -- |
Sanara Medtech Inc | 72.41m | -6.57m | 302.65m | 107.00 | -- | 7.26 | -- | 4.18 | -0.7788 | -0.7788 | 8.62 | 4.77 | 1.10 | 1.86 | 8.13 | 676,731.00 | -10.16 | -17.73 | -12.08 | -22.07 | 89.73 | 88.08 | -9.23 | -17.13 | 1.49 | -4.88 | 0.2577 | -- | 41.77 | 61.93 | 45.79 | -- | 99.09 | -- |
Holder | Shares | % Held |
---|---|---|
Viking Global Investors LPas of 30 Jun 2024 | 1.79m | 12.35% |
Perceptive Advisors LLCas of 30 Jun 2024 | 1.06m | 7.35% |
BlackRock Fund Advisorsas of 30 Jun 2024 | 624.04k | 4.31% |
Walleye Capital LLCas of 30 Jun 2024 | 475.00k | 3.28% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 463.91k | 3.21% |
Slotnik Capital LLCas of 30 Jun 2024 | 341.61k | 2.36% |
Millennium Management LLCas of 30 Jun 2024 | 303.20k | 2.09% |
TIG Advisors LLCas of 30 Jun 2024 | 243.65k | 1.68% |
Morgan Stanley & Co. LLCas of 30 Jun 2024 | 235.56k | 1.63% |
Ikarian Capital LLCas of 30 Jun 2024 | 230.00k | 1.59% |